Abstract:Background: Members of the inhibitor of DNA-binding (ID) family of helix-loop-helix proteins have been causally implicated in the pathogenesis of several types of B-cell lineage malignancy, either on the basis of mutation or by altered expression. B-cell chronic lymphocytic leukemia encompasses a heterogeneous group of disorders and is the commonest leukaemia type in the Western world. In this study, we have investigated the pathobiological functions of the ID2 and ID3 proteins in this disease with an emphasis on their role in regulating leukemic cell death/survival. Methods: Bioinformatics analysis of microarray gene expression data was used to investigate expression of ID2/ID3 in leukemic versus normal B cells, their association with clinical course of disease and molecular sub-type and to reconstruct a gene regulatory network using the 'maximum information coefficient' (MIC) for target gene inference. In vitro cultured primary leukemia cells, either in isolation or co-cultured with accessory vascular endothelial cells, were used to investigate ID2/ID3 protein expression by western blotting and to assess the cytotoxic response of different drugs (fludarabine, chlorambucil, ethacrynic acid) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. ID2/ID3 protein levels in primary leukemia cells and in MEC1 cells were manipulated by transduction with siRNA reagents. Results: Datamining showed that the expression profiles of ID2 and ID3 are associated with distinct pathobiological features of disease and implicated both genes in regulating cell death/survival by targeting multiple non-overlapping sets of apoptosis effecter genes. Consistent with microarray data, the overall pattern of ID2/ID3 protein expression in relation to cell death/survival responses of primary leukemia cells was suggestive of a pro-survival function for both ID proteins. This was confirmed by siRNA knock-down experiments in MEC1 cells and in primary leukemia cells, but with variability in the dependence of leukemic cells from different patients on ID protein expression for cell survival. Vascular endothelial cells rescued leukemia cells from spontaneous and cytotoxic drug-induced cell death at least in part, via an ID protein-coupled redox-dependent mechanism. Conclusions: Our study provides evidence for a pro-survival function of the ID2/ID3 proteins in chronic lymphocytic leukemia cells and also highlights these proteins as potential determinants of the pathobiology of this disorder.

A study of the relationship between circulating cytokines (interleukin-2 receptor and tumor necrosis factor receptor 2) and risk of B-cell non-hodgkin lymphoma

[Study on Expression of Caspase-3 and Bcl-2 Proteins and Their Relations with Cell Apoptosis and Proliferation in Non-Hodgkin's Lymphoma].

Distinct Role of Interleukin-6 and Tumor Necrosis Factor Receptor-1 in Oval Cell- Mediated Liver Regeneration and Inflammation-Associated Hepatocarcinogenesis

Clinical significance of T-regulatory cells in B-cell non-Hodgkin's lymphoma

Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma

Effects of Hepatitis B Virus Infection on the Serum Levels of TNF-α, Sil-2R, IL-6, and IL-10 in Patients with Diffuse Large B Cell Lymphoma

Effect of CD4~+ T cells on the induction of differentiation of autologous non-Hodgkin B-cell lymphoma cells in vitro

Noncoding RNAs in B cell non-Hodgkins lymphoma

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

Prognostic value of some inflammatory markers in patients with lymphoma

Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study

B cell regulation of the anti-tumor response and role in carcinogenesis

Tumor-related interleukins: old validated targets for new anti-cancer drug development

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

57: EVALUATION OF THE CIRCULATING LEVELS OF IL-12 AND IL-33 IN PATIENTS WITH BREAST CANCER: INFLUENCES OF THE TUMOR STAGES AND CYTOKINE GENE POLYMORPHISMS

ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro

The study of cytokines profile of lymphocyte in pleural effusion of non-small cell lung cancer patients at the single cell level

Cytotoxic CD4~+ T clones as effector cells in B cell non-Hodgkin's lymphoma

[Expression and Clinical Significance of Cytokines and Lymphocyte Subsets in Patients with Diffuse Large B-Cell Lymphoma]

Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response